Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
View Patent ↗Methods of treating orthostatic hypotension are disclosed. The methods include administering to a subject in need thereof an effective amount of a beta 2 (β2) adrenoceptor antagonist, and in particular, the specific β2 adrenoceptor antagonist, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol.
1. A method for treating orthostatic hypotension in a subject in need thereof, the method comprising administering a therapeutically effective amount of a β2-adrenoceptor antagonist to the subject, wherein the β2-adrenoceptor antagonist is 3 (isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol.
2. The method of claim 1 wherein the subject is administered from about 1 μg/kg/hr to about 5 μg/kg/hr of the β2-adrenoceptor antagonist for a period of about 7 days.
3. The method of claim 1 wherein about 10 mg to about 40 mg of the β2-adrenoceptor antagonist is orally administered to the subject.
4. The method of claim 1 wherein the subject is an elderly subject.
5. A method for treating dizziness resulting from orthostatic hypotension in a subject in need thereof, the method comprising administering a therapeutically effective amount of a β2-adrenoceptor antagonist to the subject, wherein the β2-adrenoceptor antagonist is 3 (isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol.
6. The method of claim 5 wherein about 1 μg/kg/hr to about 5 μg/kg/hr of the β2-adrenoceptor antagonist is administered to the subject for a period of about 7 days.
7. The method of claim 5 about 10 mg to about 40 mg of the β2-adrenoceptor antagonist is orally administered to the subject.